SINT Stock Forecast & Price Target

SINTX Technologies is transitioning from a science-driven biomaterials developer into a commercial orthopedic and biomaterials company, and that shift is supported by tangible operating progress rather than hype. In 1Q26, revenue was $0.38M, up 3% y/y, with continuing-operations product revenue up 32% and grant/contract revenue up 142%, while excluding the divested TA&T business, remaining revenue rose 46% y/y, signaling improving underlying demand. The October 2025 FDA 510(k) clearance, March 2026 first-in-human procedure, and 2026 milestones tied to SINAPTIC, Evonik, and other OEM opportunities create multiple catalysts in a large ~$5B foot and ankle market with attractive infection and healing advantages.

SINTX Technologies is facing a weak fundamental backdrop because it ended 1Q26 with only $1.9M of cash, creating clear liquidity and going-concern risk as it tries to fund commercialization and pipeline expansion. Operating leverage is deteriorating, with total operating expenses rising 34% y/y to $3.35M while gross profit was only $0.144M, and higher G&A plus sales and marketing spending suggest the business is consuming cash faster than it is generating revenue. The outlook is further pressured by dependence on surgeon adoption, regulatory and reimbursement success, partnership execution, and competition from established orthopedic players, all of which make near-term commercial traction difficult to prove.